Improving HIV prevention care with MISTR
Part of Immune system & allergy, Infections clinical trials.
This study looks at how to improve the start and continued use of PrEP, a daily pill that prevents HIV, through the MISTR telemedicine service. It aims to help people who use MISTR stay on PrEP and protect their health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You use the MISTR service for your healthcare.
- You live in the United States.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at prescribing PrEP (medication to prevent HIV) in regular doctor's offices. It may help you get easier access to prevention if you're at higher risk.
This study looks at ways to improve PrEP (pre-exposure prophylaxis) care by helping clinic staff track and support patients better. It's for healthcare workers, managers, and data staff at certain PrEP clinics.
This study tests a support program to help people stick with PrEP, a daily pill that prevents HIV. If you've stopped taking PrEP or are thinking about restarting, this program may help you stay protected.
This study helps pharmacies that do not yet offer PrEP (the daily medicine that prevents HIV) learn how to start. It provides training and support on the basics of PrEP and how to make it financially sustainable.
This study tests a program to help men who use stimulants and are at risk for HIV reduce drug use and prevent HIV infection. Participants may get access to PrEP, a daily pill that prevents HIV, and support to lower their risk.
This study helps young people who are at risk for HIV get on PrEP—a daily pill or shot that prevents HIV. It tests different ways to help you start and stay on PrEP, with care available at clinics or in your community.
Hear when a new Human Immunodeficiency Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.